Who Paid My Doc
Rahul Dutta
Urogynecology and Reconstructive Pelvic Surgery Winston Salem, NC Medical Doctor
NPI 1770080368 CMS profile 11288945
1 Medical Center Blvd, Ste C925, Winston Salem, NC 27157
General payments
$13,233
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Rahul Dutta of Winston Salem, NC is reported in the CMS Open Payments database as having received $13,233 across 49 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 66th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $784 | 9 | |
| 2024 | General | $11,116 | 21 | |
| 2023 | General | $652 | 9 | |
| 2022 | General | $331 | 4 | |
| 2021 | General | $349 | 6 |
Beside peers
- Rahul Dutta
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Rahul Dutta were reported at $784. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.
Show as a table
| Year | Rahul Dutta | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $799 | $319–$2,013 | $163 |
| 2020 | $0 | $384 | $158–$1,360 | $114 |
| 2021 | $349 | $641 | $247–$2,515 | $132 |
| 2022 | $331 | $843 | $347–$2,794 | $149 |
| 2023 | $652 | $819 | $308–$2,302 | $160 |
| 2024 | $11,116 | $882 | $306–$2,459 | $164 |
| 2025 | $784 | $779 | $301–$2,705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
477
Drug cost
$165,568
Branded share of claims
54.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 103 | $79,604 | |
| Myrbetriq Mirabegron | Brand | 92 | $65,154 | |
| Estradiol | Generic | 108 | $6,943 | |
| Premarin Estrogens, Conjugated | Brand | 14 | $5,951 | |
| Methenamine Hippurate | Generic | 47 | $3,659 | |
| Estradiol (Twice Weekly) Estradiol | Brand | 11 | $1,300 | |
| Trospium Chloride | Generic | 18 | $1,264 | |
| Solifenacin Succinate | Generic | 23 | $1,050 | |
| Tamsulosin Hcl | Generic | 23 | $348 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 25 | $266 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Records
49 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in North Carolina
Related records
Urogynecology and Reconstructive Pelvic Surgery in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.